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Abstract 
Enterococcus faecium are robust opportunistic pathogens that are most 














survive in the environment. Since the introduction and use of antimicrobials, E. 
faecium have been found to rapidly acquire resistance genes which when 
expressed can effectively circumvent the effects of most antimicrobials. The 
rapid acquisition of multiple antimicrobial resistances has led to the adaptation 
of specific E. faecium clones in the hospital environment collectively known as 
clonal complex (CC)17. CC17 E. faecium are responsible for a significant 
portion of hospital-associated infections, which can cause severe morbidity and 
mortality. Here, we review the history of E. faecium from commensal to a 
significant hospital-associated pathogen, its robust phenotypic characteristics, 
commonly used laboratory typing schemes and antimicrobial resistances with a 
focus on vancomycin and its associated mechanism of resistance. Finally, we 
review the global epidemiology of vancomycin resistant E. faecium and 
potential solutions to problems faced in public health.  
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1. Introduction 
Over the last three decades, Enterococcus faecium is a species of bacterium that 
has ranged from being considered a commensal which could be used as used as 
probiotic to an ESKAPE pathogen (a list of the leading causes of nosocomial 
bacterial infections) (1). Although ubiquitous in the environment, E. faecium is 














However, in an immunocompromised host, E. faecium can behave as an 
opportunistic pathogen causing severe morbidity and mortality. Furthermore, E. 
faecium can resist the effect of many antimicrobials through the rapid 
acquisition of antimicrobial resistance genes which effectively circumvents 
modern day medicine.  In this review, we have focused on hospital associated 
Clonal Complex (CC) 17 E. faecium and the impact it has on public health. 
2. The Past 
Thiercelin first described a bacterium termed “Entérocoque” (French) in 1899 
as a diplococcus bacteria inhabiting the gut (2).  The English translation, 
Enterococcus, was later adopted to broadly describe the genus consisting of 
Gram-positive bacteria that are homofermentative lactobacillales of the 
firmicutes phylum. The Enterococcus genus is associated with strong survival 
traits that can overcome broad temperature fluctuations (10 - 45°C), wide pH 
gradients (pH 4.5 - 10.0), high NaCl concentrations (6.5%) (3), survive heat 
exposure of up to 80°C for 33 minutes, and have variable tolerance to sub-
clinical concentrations of chemical disinfectants such as alcohol and 
chlorhexidine (4, 5). The haemolytic ability of enterococci is mediated by the 
expression of cytolysin which is commonly encoded on plasmids but can also 
be found on the chromosome (6). 
2.1  The rise of a genus 
Before the Enterococcus genus was established, enterococci were members of 
the Streptococcus genus and were further classified as Group D Streptococcus 
using the Lancefield serological typing scheme (7). Using molecular 














between S. faecalis and S. faecium with other members of the streptococci 
family to establish a new genus, they termed Enterococcus (8). The two species 
S. faecalis and S. faecium were subsequently re-named Enterococcus faecalis 
and E. faecium. Over 50 additional species have subsequently been re-classified 
or newly identified as enterococci. 
Although enterococci were identified as a molecularly distinct genus, 
phenotypic identification using traditional laboratory tests are difficult due to 
the lack of common traits amongst species of the genera. Presumptive 
identification is made based on the isolate (i) growing in 6.5% NaCl at 45°C; (ii) 
hydrolysing esculin in the presence of bile salts (bile-esculin test); (iii) 
hydrolysing leucine-β-napthylamide by producing leucine aminopeptidase 
(LAPase test); (iv) and hydrolysing L-pyrrolidonyl-β-napthylamide by 
producing pyrrolidonyl arylamidase (PYR test). Species and genus 
identification for enterococci however can also be performed by a microbiology 
laboratory within minutes using matrix-assisted laser desorption ionization – 
time of flight mass spectrometry (MALDI-TOF MS) (9). 
2.2 Splitting of the species 
To understand why some E. faecium are clinically important while others remain 
commensals, two studies have examined the evolution of the species. Galloway- 
Peña et al. (10) and Lebreton et al. (11) described two distinct E. faecium clades, 
one accounting for hospital-associated (HA) isolates and the other accounting 
for community-associated (CA) isolates. Using synonymous single nucleotide 
polymorphism (sSNP) molecular clock estimate with E. coli parameters, 















Lebreton et al., using Bayesian evolutionary analysis on sampled phylogenetic 
trees (BEAST) excluding recombinations, describes a more complex 
evolutionary path with two divisions. The first bifurcation, which they 
postulated stemmed from increased urbanization and domestication of animals, 
was estimated to have occurred around 2,776 ± 818 years ago and divided the 
species into human and animal dominant clades. The animal clade further 
divided into an epidemic hospital clade (A1) and a clade that causes sporadic 
infections in animals and human in the community (A2). The division was 
thought to have occurred as a result of the introduction and use of antimicrobials 
in hospitals and animal feed approximately 74 ± 30 years ago. 
2.3 Typing 
Using multilocus sequence typing (MLST), which characterizes the loci within 
seven E. faecium housekeeping genes, (atpA, ddl, gdh, purK, gyd, pstS and adk), 
E. faeium can be divided into genetic lineages known as sequence types (ST) 
(12). ST17 was identified as the ancestral clone of the hospital associated clade 
(A1) which has since been re-named clonal complex (CC)17 (13). The majority 
of hospital associated E. faecium isolates have since been identified as members 
of CC17 (Figure. 1). 
Although MLST is an important method for typing isolates, considerable 
sequence diversity has been observed between clinical isolates of E. faecium 
with the same ST (14, 15). Recently, Carter et. al identified several E. faecium 
that could not be typed by MLST due to the loss of the required housekeeping 
gene, pstS (16). Whole genome sequencing studies have shown genetic diversity 
within E. faecium may have already crossed a degree of divergence usually 














which takes into account genetic changes throughout the whole genome would 
be more appropriate for typing E. faecium isolates. 
For now, the use of MLST in surveillance can still serve to signal the emergence 
of a new ST of E. faecium at a particular facility or geographical area. The early 
identification of new E. faecium STs at a hospital may lead to preemptive 
infection control, particularly if the STs have previously been characterized as 
highly pathogenic. 
3. The Present 
3.1 The Start of the Antimicrobial Era 
As opportunistic pathogens, E. faecium infections primarily occur in immune 
compromised patients and therefore pose a serious threat to those in intensive 
care, burns, oncology and organ transplant units. In the late 1970s, enterococci 
infections became increasingly prominent in hospitals mirroring the introduction 
and use of third generation cephalosporins to which all enterococci are 
intrinsically resistant to. A decade later, in the United States of America (USA), 
the first reports of an increase in infections and outbreaks due to ampicillin 
resistant enterococci were published (17). As a result, vancomycin was 
introduced as a treatment option. However, reports of vancomycin resistance 
enterococci (VRE) emerged not long after . 
By the early 1990s, VRE had become the second most common nosocomial 
pathogen in the USA (18) and was endemic in many North American hospitals 
(19). It has been hypothesized the increase in VRE colonization and infection in 














Europe, VRE colonization and infection dramatically increased over a short 
period of time. However, unlike the USA, a large community reservoir was 
thought to be the reason for the sudden increase in VRE colonization and 
infection. In the late 1980s, farmers in Europe began supplementing animal feed 
with avoparcin, a glycopeptide antimicrobial similar to vancomycin. Evidence 
of VRE colonization was soon observed in farm animals and also in the 
community (21). The use of avoparcin in animal husbandry was subsequently 
banned in Europe in 1996. However persisting VRE colonization in poultry has 
been reported up to eight years after the ban (22). 
3.2 To survive is to adapt 
The rapid adaptation to antimicrobials can be attributed to the hyper-mutable 
DNA of E. faecium. Studies have consistently identified multiple recombinant 
regions consisting up to 26% of the E. faecium genome (23). It is believed the 
lack of the CRISPR-CAS loci, which protects genomic DNA from extracellular 
DNA in other bacteria, results in the high recombination rates observed in E. 
faecium (24). In addition, E. faecium are able to acquire and disseminate genes 
rapidly through mobile genetic elements (MGEs) such as plasmids and 
transposons which are ubiquitous among bacteria (25). MGEs usually carry gene 
cassettes consisting of virulence factors and antimicrobial resistance genes. 
3.3 Plasmids 
Plasmids are extrachromosomal DNA encoding non-essential genes which can 
be transmitted through donor-recipient interactions (26). The genomic content 
of plasmids are plastic and dynamic and can encode for functions such as 
maintenance, resistance and pathogenicity (27). As a result, classification of 














In 2010, a novel plasmid classification system was introduced for enterococci 
and other Gram-positive bacteria.  The classification was based on the sequence 
homology of replication initiating genes (rep) which are essential for plasmid 
replication and maintenance (28). In the same study, plasmids identified in E. 
faecium were categorized into six of the 19 known rep families (2, 4, 11, 14, 18). 
The most prominent rep-family identified were rep2 (45%) and rep14 (31%), 
found in isolates from animal and human origin. 
3.4 Transposons 
Either composite or non-composite transposons are chromosomally encoded 
DNA sequences that can be excised and transferred through mechanisms similar 
to that of plasmids. Once transferred, the transposon is able to insert itself into 
the chromosome. In E. faecium, composite transposons such as Tn1547  confers 
vancomycin type B (vanB) resistance and are flanked by insertion sequences 
(IS). Tn1546, a derivative of Tn3, a replicative transposon which confers 
vancomycin type A (vanA) resistance, does not contain flanking IS elements 
(29, 30).  
The ability to share MGEs allow E. faecium to accumulate and share beneficial 
traits that provide an advantage. As a result, E. faecium can rapidly adapt its 
genome to overcome stressful environmental conditions. 
3.5 A pathogen is only as bad as its virulence factors 
The virulence of a bacterium provides a quantitative measure of its ability to 
cause disease. Virulence factors are specific traits found in bacteria that results 














such as bacterial toxins, cell surface adhesins that mediate bacterial attachment, 
protective cell surface proteins and secreted exoenzymes (31).  
3.5.1  Adhesion 
The adherence of the bacterial cell to host cells is the first step in establishing 
infection. The extracellular matrixes of host cells play an important role in cell 
function and are also prime targets for bacterial adhesion. Microbial surface 
component recognizing adhesive matrix (MSCRAMM) are a subset of adhesion 
factors which mediate initial attachment (14). Included in the MSCRAMM 
family of genes for E. faecium are ace, acm, scm and ecba, of which, ace and 
acm share homologous domains to cna, the collagen-binding Staphylococcus 
aureus MSCRAMM.  
3.5.2 Aggregation substances 
Aggregation substances are another class of adhesins carried by E. faecium 
which are encoded on inducible sex pheromone plasmids. As well as promoting 
adhesion to bacterial cell, in vitro aggregation substances enhance adhesion to a 
variety of eukaryotic cell surfaces. The enterococci surface proteins (ESP), is a 
high molecular weight surface protein that influences enterococci pathogenesis 
(32).  A high correlation has been observed between the presence of ESP and 
the ability to form biofilms (P<0.0001) (33). The CC17 hospital-adapted E. 
faecium has been characterized by harboring an ESP containing pathogenicity 
island (34). 
3.5.3 Exoenzymes 
Exoenzymes are enzymes produced by the bacterial cell that are secreted 














In E. faecium the gelatinase exoenzyme is a metalloendopeptidase encoded by 
gelE which is capable of degrading a wide range of host substrates such as 
insulin, casein, hemoglobin, fibrinogen, collagen and gelatin. gelE is also able 
to clear the bacterial surface of misfolded proteins and activating autolysin (36). 
A second exoenzyme present in E. faecium is hyaluronidase which can cause 
tissue damage by catalyzing hyaluronic acid, a component in the extracellular 
matrix of connective tissues. It has been suggested E. faecium produces 
hyaluronidase to break down host hyaluronic acid into simpler substrates which 
are transported and metabolized in the bacterial cell supplying it with nutrients 
(37). A third exoenzyme, cytolysin, which is encoded in an operon of eight genes 
either on a plasmid or in the chromosome, targets host erythrocytes, 
macrophages and polymorphonuclear leukocytes triggering an inflammatory 
process (38, 39). In addition to host cell destruction, cytolysin is also a 
bacteriocin which targets other Gram-positive bacteria (40).  
3.6 Intrinsic Antimicrobial Resistance 
3.6.2 Aminoglycosides 
Due to its Gram-positive cell wall, all enterococci are naturally resistant to low 
levels of aminoglycosides (41). However, when antimicrobials with bacterial 
cell wall activity, such as β-lactams, are used synergistically, aminoglycoside 
uptake in E. faecium can be increased.  
E. faecium may also expresses a chromosomally encoded 6'-N-aminoglycoside 
acetyltransferase which cleaves the 6’-amino group of several aminoglycosides 
(42). The slow rate of enzymatic activity results in a moderate level of 














may be attained by the acquisition of genes encoding for a variety of 
aminoglycoside modifying enzymes such as 2”-phosphotransferase-6’-
acetyltransferase (ACC(6’)-APH(2”)) which allows the isolate to survive 
concentrations >1000 µg/mL (43). The loss of efficacy of aminoglycoside has 
resulted in the loss of all aminoglycoside based synergistic antimicrobials . 
3.6.3 Cephalosporins 
Cephalosporins are broad-spectrum β-lactam antibiotics which have low toxicity 
and hypoallergenic properties (44). E. faecium are intrinsically resistant to 
cephalosporin concentrations of >10,000 µg/ml. Cephalosporins, such as 
ceftriaxone, can reach biliary concentrations of 5,000 µg/ml which virtually kills 
all upper gastrointestinal bacteria other than E. faecium. Studies have found an 
increased proportion of enterococci in the gastrointestinal tract of volunteers 
after given oral cephalosporin (44). The removal of cephalosporin-susceptible 
bacteria increases the colonisable area and the risk of E. faecium infection (45).  
3.7 Acquired Antimicrobial Resistance 
3.7.2 Beta-lactams 
Because of their ability to inhibit the synthesis of essential cell wall 
peptidoglycan, ampicillin and penicillin were the most effective β-lactams 
against E. faecium. Penicillin’s low affinity towards eukaryotic cells are an 
added benefit when used in vivo. Many E. faecium however have acquired high 
level β-lactam resistance through the modification of the penicillin binding 
protein (PBP) 5 gene which results in: (i) a decreased β-lactam affinity due to a 
modified protein product; (ii) an increased β-lactams tolerance due to an up-














which can increase resistance exponentially (46). E. faecalis may be 10 - 100 
times less susceptible to β-lactams such as penicillin compared to most 
streptococci and E. faecium may be resistant a further 4 - 16 times.  
E. faecium can also acquire the blaZ gene coding for a β-lactamase enzyme (47). 
The enzyme inactivates β-lactams by cleavage of the β-lactam ring. Sequence 
studies have shown that the blaZ genes found in enterococci are similar to the 
blaZ gene found in S. aureus suggesting a cross species origin (48). However, 
unlike staphylococci, expression of β-lactamase in enterococci is constitutively 
low hence a high inoculation concentration is required to ensure sufficient β-
lactamase production results in penicillin resistance .  
3.7.3 Vancomycin 
Preceded by an increase in infections and outbreaks caused by ampicillin-
resistant enterococci, clinically significant isolates of VRE were subsequently 
detected in the United Kingdom (49) and Europe (50) and shortly after in the 
USA (18). By the early 1990s, VRE had become the second most common 
nosocomial pathogen in the USA (18) and was endemic in many North 
American hospitals (19).  
In Australia, the first reported vancomycin resistant E. faecium (VREfm) was 
a vanA E. faecium from a liver transplant recipient in 1995 (51). Since then, the 
vast majority of VRE isolated in Australia have been E. faecium harboring 
the vanB operon (52). Although prevalence or incidence rates of VREfm in 
Australian hospitals are not routinely collected, several studies have shown a 
significant increase in the number of patients infected or colonized with vanB E. 














(AGAR) Australian Enterococcal Sepsis Outcome Program (AESOP) reported 
46.5% of E. faecium isolates vancomycin resistant, of which 58.9% 
were vanB resistant (see http://www.agargroup.org/surveys). 
Three of the ten known van genes (vanA, vanB and vanM) carry greater clinical 
significance as they are able to confer intermediate to high levels of resistance 
towards vancomycin and are encoded on mobile genetic elements.  The 
remaining seven known van genes (vanC, vanD, vanE, vanF, vanG, vanL and 
vanN) typically confer lower levels of resistance and/or are not transferable and 
therefore they do not pose a high risk to public health. The highest level of 
vancomycin tolerance for wild-type E. faecium also known as the 
epidemiological cut-off value (ECOFF) is 4 µg/ml (55). The vanA and vanM 
types characteristically encode for high levels of inducible vancomycin 
resistance (MIC, 64 - 1,000 µg/ml & ≥ 256 µg/ml respectively) which are clearly 
distinguishable from wild-type by phenotypic antimicrobial susceptibility tests 
(ASTs). The vanB operon, encodes for a variable level of inducible vancomycin 
resistance (MIC, 0.5 - ≥ 256 µg/m) which overlaps with wild-type distributions 
(56).  
The vanA, vanB and vanM type also differ in their geographical distributions 
with vanA more predominant in North America, Europe, Iran, China whilst 
vanB is predominant in Australia, New Zealand, Singapore, England, Wales and 
Scotland (56-61). vanM, so far has only been reported in China and Singapore 
(62, 63). However the geographical distribution of vanM may be underestimated 
as commercial molecular test kits routinely used in microbiology diagnostic 














3.8 Mechanism of vancomycin resistance  
In the normal synthesis of cell wall peptidoglycan, a racemase enzyme initially 
converts L-alanine to D-alanine in the bacterial cytoplasm (64). A ligase 
combines two D-Ala molecules together as a dipeptide which is added to uracil 
diphosphate–N-acetylmuramyl-tripeptide to form uracil diphosphate–N-
acetylmuramyl-pentapeptid. The pentapeptide is bound to an undercaperol lipid 
carrier which, after the binding of N-Acetyl-D-glucosamine, is allowed to 
translocate to the outer surface of the cytoplasm (Figure 2). The pentapeptide is 
added to newly formed peptidoglycans via transglycosylation and anchored by 
transpeptide cross-bridges.  
 
The key to the potent antimicrobial effect of glycopeptides on enterococci relies 
on the binding of the glycopeptide to the D-Ala-D-Ala at the C-Terminus end of 
the translocated pentapeptide. The binding prevents subsequent 
transglycosylation, transpeptidation and carboxypeptidase reactions. 
Modifications to the D-Ala-D-Ala dipeptide mediated by the van genes reduces 
the affinity of vancomycin binding by up to 1,000 times and thus losing its 
efficacy (65).  
3.9 Structure of the van operon 
The vanA operon consist of three major components: Regulation (vanR and 
vanS), glycopeptide resistance (vanH, vanA and vanX) and accessory genes 
(vanY and vanZ) (Figure 2). In vanA type resistance, a dehydrogenase enzyme 
encoded by vanH reduces pyruvate to D-Lac. The ligase encoded by the vanA 
gene then catalyses an ester bond between D-Ala and D-Lac (66). The resulting 














reduction in vancomycin affinity (65). It is important to note the simultaneous 
production of D-Ala-D-Ala and D-Ala-D-Lac precursors does not result in 
significant increase in vancomycin resistance as sufficient vancomycin binding 
to D-Ala ending peptidoglycans still renders the cell susceptible (66). It is 
therefore necessary for the removal of susceptible D-Ala-D-Ala precursors for 
high levels of resistance. For this to occur, a D,D-dipeptidase encoded by vanX 
hydrolyses the susceptible D-Ala-D-Ala dipeptide into two D-Ala peptides (67). 
A D,D-carboxypeptidase encoded by vanY cleaves remaining D-Ala at the C-
terminus end of developing peptidoglycans left behind by vanX  (68). The two 
enzymes coded by vanX and vanY ensures the removal of susceptible D-Ala-D-
Ala binding sites for glycopeptides.  
The vanB type operon’s structure is similar to the vanA operon. It contains a 
dehydrogenase, a ligase and a dipeptidase gene component that has a 67-76% 
sequence homology with its vanA counterpart. Therefore, it is not surprising that 
the D-Ala-D-Ala peptidoglycan precursor for vanB is replaced with D-Ala-D-
Lac by the same processes as described for vanA (66). Although the vanA and 
vanB type resistance is induced by teicoplanin and vancomycin respectively, the 
transcriptional activation of both operons follow the same mechanisms (Figure 
4). Although the vanB type is not commonly known to carry teicoplanin 
resistance, evidence of a novel vanB2 teicoplanin resistant variant has been 
identified (69). The vanB operon has an additional vanW gene but do not have 
the vanZ gene compared to the vanA operon (Figure 3).  
Based on the sequence difference, the vanB type operon has been subdivided 
into three subtypes: vanB1, vanB2 and vanB3 (70, 71). The three subtypes have 














McGregor et al. on the prevalence of the vanB2 gene examined 204 enterococci 
isolates from 59 hospitals in England, Wales, Scotland and the Republic of 
Ireland, and showed 202 (99%) isolates carrying the vanB2 gene (60). Analysis 
of the conjugative transposon, Tn5382, which carries the vanB2 gene, suggest 
horizontal gene transfer was responsible for its dominance (60). In Australia, we 
have identified the vanB2 subtype in 94.85% of 251 vanB positive E. faecium 
with the remaining isolates carrying the vanB1 subtype (unpublished data).  
The vanM type resistance consists of 1,032bp encoding a 343 amino-acid 
protein which shares approximately 80% sequence identity with vanA. The 
vanM does not  possess the vanZ or vanW component (72). The vanM type, like 
vanA, vanB and vanF confers vancomycin resistance through the inducible 
synthesis of precursors ending in D-Ala-D-Lac. The operon organization 
however mostly resembles that of vanD. Upstream of the vanM cluster lies an 
IS-1216-like element which may account for its dissemination akin to the IS-
1216V element found widely in vanA types by transposon-mediated fusion 
of vanA plasmids with other plasmids (26, 73, 74).  
The vanD operon which is only found in E. faecium, is exclusively located on 
the chromosome and cannot participate in horizontal gene transfer (75). 
Although vancomycin and teicoplanin resistance conferred by the vanD gene 
cluster are typically low, they can reach concentrations of up to 256 µg/mL and 
64 µg/mL respectively. The organization of the vanD operon is similar to that 















The other van operons, vanC, vanE, vanG, vanL and vanN produce 
peptidoglycan precursors ending in D-Ala-D-Ser to which glycopeptides have a 
lower binding affinity (76-78). Therefore, enterococci harbouring the vanC, 
vanE, vang, vanL or vanN operons are usually resistant to low vancomycin 
concentrations of up to 32 µg/mL. The vanC operon, intrinsically found in E. 
gallinarum and E. casseliflavus, provides resistance to vancomycin. The 
biochemically and phenotypically similar vanE operon is only found in E. 
faecalis. 
3.10 Epidemiology 
E. faecium have the ability to survive in extreme conditions, are ubiquitous in 
the environment and highly prevalent in the natural gut microbiome. Surveys 
have isolated E. faecium from wild animals including birds and insects. In the 
environment, soil and water bodies such as rivers, ponds and waste water have 
also been identified as reservoirs for E. faecium (79). In Portugal, antimicrobial 
resistant E. faecium were recovered from fecal samples of wild rabbits, badgers, 
forest wildcats, storks, quails, wolf, birds of prey and sewage (80, 81). A 
separate study also identified ST18 CC17 E. faecium from the fecal sample of a 
wild Ibreian wolf in Northeast Portugal indicating the presence of CC17 E. 
faecium in native wildlife (82). Elsewhere, CC17 E. faecium have been reported 
in wild corvid birds in USA, slovakia and the Czech republic (83, 84). Although 
there were many other reports of multi-drug resistant E. faecium from wildlife, 
most studies did not perform MLST. 
In the environment, waste water is often been reported as a reservoir for CC17 
E. faecium. A comprehensive study in the south coast of England focusing on 














and farm run-off water identified CC17 E. faecium belonging to an epidemic 
group associated with outbreaks in UK, the Netherlands, the USA and Australia 
(85). Two other independent studies performed on the effluent waters of  two 
waste water treatment plants in Gdansk, Poland, and a river downstream of a 
plant in the northwest of France, also recovered CC17 E. faecium but noted that 
those isolates were in a minority (86, 87).  
Besides wild animals and the environment, CC17 E. faeicum has also manage 
to adapt to domestic animals. The carriage of CC17 E. faecium in domestic 
animals results in an increased risk of zoonotic transfer to humans. The 
prevalence of CC17 E. faecium in companion animals is well documented 
internationally (88-91). In Portugal, CC17 E. faecium isolates identified in 
companion cats and dogs were resistant to ampicillin and/or high-level 
gentamicin (88). In Korea, it was reported that ampicillin and ciprofloxacin 
resistance were high in CC17 E. faecium isolated from companion dogs and 
humans while tetracycline resistance was more commonly identified in isolates 
from companion dogs. Additionally, vancomycin resistant isolates were only 
found in CC17 E. faecium isolated from humans (89). The findings suggest 
CC17 E. faecium may possess advantages for infecting humans and animals but 
their antimicrobial resistance phenotypes may have evolved independently as a 
result of different antimicrobials used in human and veterinary medicine in 
different countries. 
Another potential route for the zoonotic transfer of CC17 E. faecium occurs 
between farm animals and humans (92). Besides direct human-animal transfer 
of CC17 E. faecium, as with companion animals, farm animals carrying CC17 














E. faecium have been recovered in swine, chickens and cows (93-95). In Spain, 
CC17 E. faecium was isolated from chicken, veal and rabbit samples, with 
isolates from all three carrying antimicrobial resistances to vancomycin, 
ampicillin, erythromycin, ciprofloxacin and high-levels of streptomycin and 
kanamycin (96). In Canadian animal farms, low quantities of CC17 E. faecium 
together with MGEs carry antimicrobial resistance genes have been identified in 
bovine fecal samples (97). 
In Portugal, CC17 E. faecium was isolated from farmed pigs and their 
surrounding environment; manure, waste lagoons, drinking water (91). In 
addition fresh vegetables sold in Portuguese supermarkets were also found to 
carry CC17 E. faecium including lettuce, green olives, celery and broccoli (98).  
Although exposure to CC17 E. faecium in the community may appear high, E. 
faecium are opportunistic pathogens therefore, community associated E. 
faecium infections are uncommon. In Europe, despite the ban of avoparcin in 
the animal industry two decades ago, colonization of VREfm in people without 
hospital contact or history of glycopeptide use can vary between ~2-28% of 
adults (99, 100). Similarly, in South Korea, which also had history of avoparcin 
use, 4.7% of farm animals and 1% of healthy individuals are reported to carry 
VREfm in their gut (101). Conversely in North America, where the use of 
avoparcin was prohibited, VREfm was not identified in the healthy adult 
population sampled (102).  
In hospitals, the two most commonly isolated species of enterococci are E. 
faecalis and E. faecium. Although E. faecalis is identified more frequently than 














observed (103). Antimicrobial resistance is more often identified in E. faecium 
(80 - 100%) compared to E. faecalis (0 - 16%) suggesting E. faecium is able to 
acquire and express resistance genes more frequently (56-58, 104-106).  
Critically ill patients such as those in intensive care units hold the highest risk 
of infection in the hospital followed by patients in hematology, neonatal and 
renal units (107). Amongst the patients in these wards, patients undergoing 
organ transplant pose the highest risk followed by patients with prolonged 
hospital stays. Prior therapy with antimicrobials that are ineffective against E. 
faecium, such as third generation cephalosporins, increases the risk of 
colonization and infection. 
 In the hospital, E. faecium remain viable on inanimate surfaces from seven days 
to two months  which increases the risk of acquiring E. faecium through factors 
such as exposure to contaminated medical equipment, proximity to patients or 
previous bed occupant shedding E. faecium and transmission by health care 
workers (108-110). A previous study which reported the low recovery of 
VREfm from rectal swabs of healthcare workers suggest healthcare workers do 
not serve as major VREfm reservoirs and VREfm colonization is uncommon in 
healthy persons .  
The spectrum of disease associated with E. faecium infection, which has 
remained relatively unchanged, was extensively reviewed by Murray in 1990 
(107). The urinary tract is the most common point of entry for enterococci into 
the blood stream, which leads to bacteremia, the leading cause of E. faecium 
morbidity and mortality (111). Other sources of E. faecium leading to blood 














significant proportion remains unknown and is assumed to originate from the 
intestinal microbiota (112, 113). E. faecium are able to translocate across the 
luminal surface of the intestines in a similar fashion to Candida albicans and 
Escherichia coli (114, 115). Secondary to BSI, enterococci account for 5-20% 
of native valve and 6-7% of prosthetic valve related bacterial endocarditis (116). 
Additionally, the vegetation of heart valves increases the risk of bacterial 
adherence enhancing the risk of infection . 
In a 2016 Australia-wide surveillance of enterococcal bacteremia which 
included 1,058 patient-episodes, 39% of isolates were E. faecium, of which 
46.5% were vancomycin resistant (117).  Compared to a related survey 
conducted in 2005, when the prevalence of vancomycin resistance in E. faecium 
was reported at 7%, the 2016 data represents a seven-fold increase in prevalence 
(118). The distribution of vanA and vanB genes in VREfm reported in the 2016 
study was 42.7% and 55.2% respectively, with four isolates carrying both sets 
of genes. The distribution of vanA to vanB VREfm isolates in 2010 was 1.6% 
and 98.4% respectively, indicating a shift in prevalence towards vanA type 
VREfm has occurred in Australia (http://www.agargroup.org/surveys). 
In the USA, the National Healthcare Safety Network (NHSN) report on hospital-
associated infections from 2011-2014 ranked E. faecium ninth overall (3.7%) 
for pathogens frequently reported (119). Approximately 83-86% of E. faecium 
collected from central-line associated blood stream infections and catheter-
associated urinary tract infections were vancomycin resistant. Comparatively 















The 2016 Canadian Antimicrobial Resistance Surveillance System (CARSS) 
report indicated a decreasing trend in the prevalence of VRE from 2012 to 2014. 
60% of  VRE cases reported in 2014 were characterized, of which, 99% were E. 
faecium and 98% carried the vanA type vancomycin resistance . 
In South America, a multicenter study involving 32 hospitals from Colombia, 
Ecuador, Perú and Venezuela, found 31% of E. faecium isolates carry the vanA 
type resistance to vancomycin (120). Additionally, all representative isolates of 
PFGE clusters subjected to MLST were identified as members of CC17 with the 
most frequent ST being ST412.  In Brazil, a study of 53 E. faecium isolates from 
patients at two university hospitals identified the vanA type vancomycin 
resistance in all isolates (121). Additionally, the 31 isolates selected for MLST 
were shown to belong to CC17 with predominantly ST412 isolates. A second 
Brazilian study also identified a ST412 CC17 vanA E. faecium resistant to 
vancomycin (>256 μg/ml) and linezolid (64 μg/ml) (122). In Cuba, two CC17 
E. faecium clones, ST656 and ST262, were resistant to ampicillin, quinolones, 
imipenem, high-level gentamicin, erythromycin, clindamycin, vancomycin, 
teicoplanin, and sulfamethoxazole/trimethoprim. 
In Europe, the European Union/European Economic Area (EU/EEA) 
population-weighted mean percentage for VREfm reported in the 2016 Annual 
report of the European Antimicrobial Resistance Surveillance Network (EARS-
Net) was 11.8% which was not significantly different than that reported in 2013 
(123). National percentages for 2016 ranged widely from 0% to 46.3% with five 
countries reporting zero VREfm cases while several European countries with 
comparatively high percentages reporting significantly increasing trends over 













In Asia, studies conducted in China predominantly reports ST78 CC17 E. 
faecium carrying the vanA type vancomycin resistance. However, vanM type 
resistance has been reported in selected areas (61, 62, 124, 125). In Malaysia, 
ST17, ST203 ST78 and ST601 E. faecium isolates belonging to CC17 were 
identified at a local hospital. In South Korea, only vanA type resistant (43/531) 
E. faecium isolates were identified in a three-year study of 212 nontertiary-
hospitals. Of the vanA E. faecium isolates, ST78 (30.2%) was the dominant ST. 
Two studies in Taiwan identified vanA type E. faecium as the dominant van type 
with ST414, ST78, ST 17 and ST18 as the dominant STs (126, 127). 
4 The Future 
VREfm outbreaks not only incur a significant cost for the healthcare system but 
also places vulnerable patients at greater higher risk of acquiring fatal infections. 
Reports of successful infection control measures that control the development 
of outbreaks have been documented on multiple occasions (54, 128, 129). Other 
reports make a synonymous point on the importance of ongoing surveillance 
(130, 131). Mathematical modelling developed by Erika et al.  predict the only 
preventative measure that could potentially eradicate VREfm from an institution 
is to prevent colonized patients from entering the hospital. This, however, is an 
unrealistic goal. The constant monitoring of VREfm carriage in high risk groups, 
such as patients admitted from long-term care facilities into vulnerable units, has 
been projected to reduce transmission significantly (132) and may be the only 
option.  
Reports documenting the successful control of VREfm outbreaks often mention 














education for healthcare workers, hand and environmental sanitization, 
antimicrobial stewardship, the use of sterile equipment and personal protective 
gear (14, 133). However, counter to these reports, it has also been reported that 
these protocols which are successful in containing other outbreaks such as that 
of methicillin resistant Staphylococcus aureus (MRSA) are inadequate for 
enterococci (14).  
Apart from preventing the spread of VREfm, the use of alternative antimicrobial 
therapy is another potential strategy to consider. Currently the two leading 
alternatives for the treatment of VREfm are linezolid and daptomycin, with 
clinical success rates of 50-80% as a first-line drug and 50-59% as salvage 
therapy for VRE bacteraemia respectively (134-137). However, resistance to 
both antimicrobials have been reported in E. faecium. Antimicrobials such as 
tigecycline and quinupristin/dalforpristin are infrequently used due to poor oral 
bioavailability, greater adverse effects or reduced activity against E. faecium. 
New therapeutic approaches such as daptomycin-β-lactam, daptomycin-
fosfomycin and daptomycin-tigecycline combination therapy may be used to 
increase treatment efficacy. Daptomycin-β-lactam regimens have shown most 
promise in in-vitro studies (138). Although new alternatives such as tedizolid, 
telavancin, oritavancin and dalbavancin have only been recently approved by 
the FDA for the treatment of VREfm, the development of new antimicrobials 
has been steadily declining over the years. Moreover, new antimicrobials such 
as tedizolid are often a derivative of older antimicrobials (linezolid) utilizing the 
same mechanism of action with some enhanced activity (139). As such, 















The fight against chronic VREfm outbreaks in hospitals is urgent and has to be 
fought on many fronts. The use of technology in typing and surveillance can 
help identify outbreaks early, allowing infection control to limit the spread of 
the outbreak. Antimicrobial stewardship practices can limit the dissemination of 
antimicrobial resistance genes in E. faecium population extending the efficacy 
of current antimicrobials. However the development of new antimicrobials is 
required to overcome the rapid adaptation observed in E. faecium. This will 
prevent a scenario where E. faecium becomes resistant to all available 
antimicrobials which will set us back decades of medical advancements due to 
the risk of untreatable infections. 
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Figure 1. eBurst –generated population snapshot of E. faecium sequence types (STs) 
associated with Clonal Complex (CC) 17 worldwide taken as of 15 December 2017 
adapted from http://efaecium.mlst.net/. Each ST is represented by a black dot. The 
numbers refer to a particular ST. The size of each dot reflects the number of isolates 
within a ST. The ancestral ST of a clonal complex is represented by a blue dot. The 
















































Figure 4 Transcriptional activation of the vanA and vanB gene clusters (141).  
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